Two colon cancer cell lines (HCT116 and LoVo) were used to verify whether the expression of insulin receptor substrate 1 (IRS‐1) could impact the half maximal inhibitory concentration (IC50) of oxaliplatin after chronic insulin treatment. This evidence concerns the gene INS and malignant colon neoplasm.